

GENE EXPRESSION MARKERS FOR RESPONSE TO EGFR INHIBITOR DRUGS

Abstract of the Disclosure

[0087] The present invention concerns prognostic markers associated with cancer. In particular, the invention concerns prognostic methods based on the molecular characterization of gene expression in paraffin-embedded, fixed samples of cancer tissue, which allow a physician to predict whether a patient is likely to respond well to treatment with an EGFR inhibitor.

SV 2002312 v1
2/5/04 9:03 AM (39740.0009)